Article

Plasma p-tau217, p-tau181, and Aβ42 Predicts Amyloid PET Positivity in Cognitively Unimpaired Adults

2026-01-20

Abstract excerpt

<title>Abstract</title> <p> <bold>Background</bold> Early detection of Alzheimer's disease (AD) pathology in cognitively unimpaired individuals is critical for preclinical intervention. Plasma biomarkers, especially phosphorylated tau217 (p-tau217), are promising predictors of amyloid-β (Aβ) accumulation. <bold>Methods</bold> In this cohort study, we analyzed data from cognitively unimpaired older adults in t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 42688329-0b9e-5033-876b-808b226b5a9f
DOI: 10.21203/rs.3.rs-8587114/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Plasma p-tau217, p-tau181, and Aβ42 Predicts Amyloid PET Positivity in Cognitively Unimpaired AdultsDOI 10.21203/rs.3.rs-8587114/v1Read

Plasma p‐tau231 and p‐tau217 inform on tau tangles aggregation in cognitively impaired individualsSemantic proximity Read

Plasma p-tau217 predicts cognitive impairments up to ten years before onset in normal older adultsSemantic proximity Read

Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unitSemantic proximity Read

Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease StagesSemantic proximity Read

A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer’s diseaseSemantic proximity Read

Age-related increase in plasma p-tau217 in amyloid-beta-negative cognitively unimpaired individuals affects diagnostic interpretation.Semantic proximity Read

A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker TestsSemantic proximity Read

Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s diseaseSemantic proximity Read

Predicting Preclinical Cognitive Decline Using Plasma P-tau217 and <i>APOE</i> Genotype in 8,582 Individuals From Different Ethnic GroupsSemantic proximity Read

CNS-selective plasma p-tau217 accurately captures Alzheimer’s disease pathology and progressionSemantic proximity Read

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measuresSemantic proximity Read

Robustness of plasma p-Tau217 diagnostic thresholds for Alzheimer’s disease across various clinical populations and laboratory environmentsSemantic proximity Read